Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II

References

• Peng K, Tian X, Qian Y, et al. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II. J Cell Mol Med. 2016;20(3):482–494.
   PubMed Web of Science ®Google Scholar
• Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65(1):45–79.
   PubMedGoogle Scholar
• Binder H, Steiner L, Przybilla J, et al. Transcriptional regulation by histone modifications: towards a theory of chromatin re-organization during stem cell differentiation. Phys Biol. 2013;10(2):026006.
   PubMed Web of Science ®Google Scholar
• Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol. 2004;18(11):2633–2648.
   PubMedGoogle Scholar
• Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev. 2002;12(2):142–148.
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12(2):198–209.
   PubMed Web of Science ®Google Scholar
• Zhang QJ, Tran TAT, Wang M, et al. Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis. Nat Commun. 2018;9(1):5230.
   PubMed Web of Science ®Google Scholar
• Zhang QJ, Chen HZ, Wang L, et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest. 2011;121(6):2447–2456.
   PubMed Web of Science ®Google Scholar
• Thienpont B, Aronsen JM, Robinson EL, et al. The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy. J Clin Invest. 2016;127(1):335–348.
   PubMed Web of Science ®Google Scholar
• Yousefi K, Irion CI, Takeuchi LM, et al. Osteopontin promotes left ventricular diastolic dysfunction through a mitochondrial pathway. J Am Coll Cardiol. 2019;73(21):2705–2718.
   PubMed Web of Science ®Google Scholar
• Luo S, Au Yeung SL, Zhao JV, et al. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. BMJ. 2019; 364:l476.
   PubMedGoogle Scholar
• Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol. 2008;52(8):655–666.
   PubMed Web of Science ®Google Scholar
• Zhao W, Chang C, Cui Y, et al. Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1alpha. J Biol Chem. 2014;289(16):11219–11229.
   PubMed Web of Science ®Google Scholar
• Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest. 2010;120(10):3520–3529.
   PubMed Web of Science ®Google Scholar
• Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93(3):246–253.
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system. Circulation. 1991;83(6):1849–1865.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang J, Varghese D, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013;4(1):2035.
   PubMedGoogle Scholar
• Duan L, Rai G, Roggero C, et al. KDM4/JMJD2 histone demethylase inhibitors block prostate tumor growth by suppressing the expression of AR and BMYB-regulated genes. Chem Biol. 2015;22(9):1185–1196.
   PubMedGoogle Scholar
• Takawale A, Zhang P, Patel VB, et al. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin beta1 interaction. Hypertension. 2017;69(6):1092–1103.
   PubMed Web of Science ®Google Scholar
• Essa EM, Zile MR, Stroud RE, et al. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012;18(6):487–492.
   PubMed Web of Science ®Google Scholar
• Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645–1654.
   PubMed Web of Science ®Google Scholar
• Szmigielski C, Raczkowska M, Styczynski G, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur Heart J. 2005;26:418. author reply 418-9.
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J. 2004;25(17):1509–1516.
   PubMed Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108–2118.
   PubMed Web of Science ®Google Scholar
• Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med. 1980;69(4):576–584.
   PubMed Web of Science ®Google Scholar
• Ikonomidis JS, Hendrick JW, Parkhurst AM, et al. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005;288(1):H149–H158.
   PubMed Web of Science ®Google Scholar
• Creemers EE, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2003;284(1):H364–H371.
   PubMed Web of Science ®Google Scholar
• Butler JS, Koutelou E, Schibler AC, et al. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics. 2012;4(2):163–177.
   PubMed Web of Science ®Google Scholar
• Lin W, Dent SY. Functions of histone-modifying enzymes in development. Curr Opin Genet Dev. 2006;16(2):137–142.
   PubMed Web of Science ®Google Scholar
• Marmorstein R, Trievel RC. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta. 2009;1789(1):58–68.
   PubMed Web of Science ®Google Scholar